Pharma & Biotech

Tilray Brands, Inc. continues to build on its strong January performance with two significant strategic developments. The cannabis and consumer...

Zevra Therapeutics continues to build its profile as a dedicated rare disease company. Recent clinical data presentations and a broadening...

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed clinical trial data...

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its complete financial results...

Biotechnology firm Quanterix has taken a pivotal step toward transforming the diagnosis of Alzheimer's disease. The company has formally submitted...

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC platform for rare...

The integration of Vigil Neuroscience into French pharmaceutical giant Sanofi has been finalized. This strategic move, which concluded in late...

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business line and finalizes...

Medical device company Embecta reported financial results for the first quarter of fiscal year 2026 on Thursday, delivering revenue and...

Investors in Viking Therapeutics are currently focused on a specific calendar event rather than breaking news. The biopharmaceutical firm is...